Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;3(1):27-34.
doi: 10.1158/2159-8290.CD-12-0462.

The genomic landscape of breast cancer as a therapeutic roadmap

Matthew J Ellis  1 , Charles M Perou
Affiliations

The genomic landscape of breast cancer as a therapeutic roadmap

Matthew J Ellis et al. Cancer Discov. 2013 Jan.

Abstract

The application of high-throughput techniques to profile DNA, RNA, and protein in breast cancer samples from hundreds of patients has profoundly increased our knowledge of the disease. The etiologic events that drive breast cancer are finally coming into focus and should be used to set priorities for clinical trials. In this Prospective, we summarize some of the headline conclusions from 6 recent breast cancer "omics profiling" articles in Nature, with an emphasis on the implications for systemic therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: PAM50 Patent and licensing

Figures

Figure 1
Figure 1
A simplified therapeutic road map based on somatic mutations in luminal-type breast cancer. This cartoon is based on the analysis by Ellis et al of luminal type breast cancers[4]. All components outlined in the cartoon were chosen based on evidence for either gene functional gain indicated in green, (e.g. amplification or gain of function mutation) or gene functional loss indicated in blue (e.g. LOH, frameshift or nonsense mutation). Matched therapeutic approaches for the gain of function events are discussed in Table 2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395–399. - PMC - PubMed
    1. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400–404. - PMC - PubMed
    1. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486:405–409. - PMC - PubMed
    1. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353–360. - PMC - PubMed
    1. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352. - PMC - PubMed

Publication types